A phase 2, multicenter, clinical trial of CPX‐351 in older patients with secondary or high‐risk acute myeloid leukemia: PETHEMA‐LAMVYX
Cancer · 2025-01 · 131 (1)
DOI: 10.1002/cncr.35618 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 30.10.2024. Verfasst von Eduardo Rodríguez-Arbolí und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS/CSIC), University of Seville, Seville, S…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jazz Pharmaceuticals.
Abstract (Originalsprache)
Background
LAMVYX was a multicenter, single‐arm, phase 2 trial designed to validate the safety and efficacy of CPX‐351 in patients aged 60–75 years with newly diagnosed, secondary acute myeloid leukemia and to generate evidence on key issues not addressed in the preceding regulatory pivotal trial.
Methods
The primary end point of the study was the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate after induction. Eligible patients were recommended to undergo allogeneic hematopoietic stem cell transplantation after the first consolidation cycle. Alternatively, patients could undergo up to six maintenance cycles with CPX‐351.
Results
Twenty‐nine patients (49%; 95% exact confidence interval [CI], 37%–62%) patients achieved a CR/CRi after one or two cycles of induction, with a measurable residual disease negativity rate of 67% as assessed by centralized, multiparameter flow cytometry. Among patients who had serial next‐generation sequencing analyses available, clearance of somatic mutations that were present at diagnosis was achieved in 7 (35%). The median follow‐up among survivors was 16.8 months (range, 8.7–24.3 months). The median event‐free survival was 3.0 months (95% CI, 1.4–7.3 months), and the median overall survival was 7.4 months (95% CI, 3.7–12.7 months). In landmark analyses at day +100 from diagnosis, the 1‐year overall and event‐free survival rate among patients who underwent allogeneic hematopoietic stem cell transplantation was 70% (95% CI, 47%–100%) and 70% (95% CI, 47%–100%), respectively. The corresponding values were 89% (95% CI, 71%–100%) and 44% (95% CI, 21%–92%), respectively, for patients who entered the maintenance phase. No significant longitudinal changes were observed in severity index or quality‐of‐life visual analog scale scores.
Conclusions
The current data provide novel insights that might inform the clinical positioning and optimal use of CPX‐351, complementing previous results (ClinicalTrials.gov identifier NCT04230239).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS/CSIC), University of Seville, Seville, Spain.
- Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- Department of Hematology, Hospital San Pedro de Alcántara, Cáceres, Spain.
- Department of Hematology, Institut Català d'Oncología, Hospital Duran i Reynals, Barcelona, Spain.
- Department of Hematology, Hospital Germans Trias i Pujol-Institut Catalá d'Oncologia, Badalona, Spain.
- Department of Hematology, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Cordoba, Spain.
ORCID-Profile: Eduardo Rodríguez-Arbolí, Susana Vives, Pau Montesinos
Förderung
- Jazz Pharmaceuticals
Zitieren
APA
Rodríguez-Arbolí, E., Rodríguez-Veiga, R., Soria-Saldise, E., Bergua, J. M., Caballero-Velázquez, T., Arnán, M., Vives, S., Serrano, J., Bernal, T., Martínez-Sánchez, P., Tormo, M., Rodríguez-Medina, C., Herrera-Puente, P., Lavilla-Rubira, E., Boluda, B., Acuña-Cruz, E., Cano, I., Cáceres, S., Ballesteros, J., …, & PETHEMA Group (2025). A phase 2, multicenter, clinical trial of CPX‐351 in older patients with secondary or high‐risk acute myeloid leukemia: PETHEMA‐LAMVYX. Cancer, 131(1). https://doi.org/10.1002/cncr.35618
Vancouver
Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, Bergua JM, Caballero-Velázquez T, Arnán M, et al. A phase 2, multicenter, clinical trial of CPX‐351 in older patients with secondary or high‐risk acute myeloid leukemia: PETHEMA‐LAMVYX. Cancer. 2025;131(1). doi:10.1002/cncr.35618
BibTeX
@article{RodrguezArbol2025,
author = {Rodríguez-Arbolí, Eduardo and Rodríguez-Veiga, Rebeca and Soria-Saldise, Elena and Bergua, Juan M and Caballero-Velázquez, Teresa and Arnán, Montserrat and Vives, Susana and Serrano, Josefina and Bernal, Teresa and Martínez-Sánchez, Pilar and Tormo, Mar and Rodríguez-Medina, Carlos and Herrera-Puente, Pilar and Lavilla-Rubira, Esperanza and Boluda, Blanca and Acuña-Cruz, Evelyn and Cano, Isabel and Cáceres, Sara and Ballesteros, Juan and Falantes, José and Martínez-Cuadrón, David and Pérez-Simón, José A and Montesinos, Pau and PETHEMA Group, PETHEMA Group},
title = {A phase 2, multicenter, clinical trial of CPX‐351 in older patients with secondary or high‐risk acute myeloid leukemia: PETHEMA‐LAMVYX},
journal = {Cancer},
year = {2025},
volume = {131},
number = {1},
doi = {10.1002/cncr.35618}
}
EUVIMED